As a World Health Assembly meeting nears, several European countries are proposing numerous changes that patient advocates argue would water down a resolution designed to create more transparency around prescription drug pricing.

At a planning session earlier this week, nearly a dozen countries — particularly Germany, Denmark, the U.K., and Sweden — offered a bevy of subtle and not-so-subtle suggestions for softening language used to describe pricing as well as for disclosing R&D costs, patent holdings, and clinical trial results, among other things. A final version, which must still be crafted, will be vetted at the WHA meeting that starts on May 20 in Geneva.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • And, this change was pretty big.

    Opt 1.3 [Require as a condition of registration for medicines, vaccines cell
    and gene-based therapies and other relevant technologies;

    a) Annual Reports on sales revenues, prices and units sold,

    b) Annual Reports on marketing costs incurred for each registered product
    or procedure,

    c) The R&D costs directly associated with each clinical trial used to support
    the registration of a product or procedure, separately, and

    d) All grants, tax credits or any other public sector subsidies and incentives
    relating to the initial regulatory approval and annually on the subsequent
    development of a product or procedure; (DEL USA, Australia, Denmark)]

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy